Moderna pushes for Covid-19 vaccine boosters in older adults, high-risk individuals
The company said its data supports the public health benefit of a booster dose of its vaccine to restore immune response, while reducing the number of "breakthrough" infections in fully vaccinated adults
Moderna Inc on Tuesday said the US Food and Drug Administration should authorize booster doses of its Covid-19 vaccine in fully vaccinated older adults and high-risk individuals.
The company said its data supports the public health benefit of a booster dose of its vaccine to restore immune response, while reducing the number of "breakthrough" infections in fully vaccinated adults.
Moderna's comments were released in briefing documents ahead of a Thursday and Friday meeting of the FDA's outside expert advisers to discuss booster doses of Moderna and Johnson & Johnson's Covid-19 vaccines.
Keep updated, follow The Business Standard's Google news channel
Rival Johnson & Johnson on Tuesday also cited data showing increased protection after a booster dose, which it said could be either administered as early as two months after the original dose of its vaccine.
